Clinical data | |
---|---|
Trade names | Alkeran, Evomela, Phelinun, others |
Other names | (2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682220 |
License data | |
Routes of administration | By mouth, intravenous, intra-arterial |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 25–89% (By mouth) |
Metabolism | Hydrolysis to inactive metabolites |
Elimination half-life | 1.5 ± 0.8 hours |
Excretion | Kidney (IV: 5.8–21.3%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.207 |
Chemical and physical data | |
Formula | C13H18Cl2N2O2 |
Molar mass | 305.20 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma.[3][4][6][7] It is taken by mouth or by injection into a vein.[7]
Common side effects include nausea and bone marrow suppression.[7] Other severe side effects may include anaphylaxis and the development of other cancers.[7] Use during pregnancy may result in harm to the fetus.[8] Melphalan belongs to the class of nitrogen mustard alkylating agents.[7] It works by interfering with the creation of DNA and RNA.[7]
Melphalan was approved for medical use in the United States in 1964.[7] It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication.[10]
Evomela FDA label
was invoked but never defined (see the help page).Phelinun EPAR
was invoked but never defined (see the help page).